© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Olanzapine stands out as an atypical antipsychotic, a key player in the world of mental health management. Clinicians rely on it to treat conditions like schizophrenia and bipolar disorder. Its chemical roots matter just as much as its therapeutic uses, since understanding structure and makeup goes hand-in-hand with safety and efficacy in any lab or production setting. The appearance of this material gives plenty of clues about its identity: most often, it shows up as a pale yellow crystalline solid. This color and texture lend it a distinct look, making it recognizable in both raw form and finished pharmaceutical products. The formula for this compound is C17H20N4S, pointing to a molecular structure supported by carbon, hydrogen, nitrogen, and a sulfur atom, which influences how it behaves under certain conditions, how it dissolves, and how it interacts during synthesis.
Getting a handle on Olanzapine’s physical traits is more than chemistry trivia. The pale yellow solid tends to appear as fine flakes, though with enough processing, it can present as powder, granules, or sometimes as tiny pearls, especially in bulk shipments. It’s not likely to be found as a liquid, and if you come across a solution, it’s usually as a result of deliberate dissolving with an appropriate solvent for analysis or compounding. These flakes or powders can clump a bit if moisture gets involved, due to their hydrophobic nature, so good storage conditions play a big role in maintaining material quality. The crystalline nature of Olanzapine also makes it a good candidate for analytical work, such as x-ray crystallography, which gives researchers a detailed look into its three-dimensional arrangement. This solid state matters for dosing precision and manufacturing processes. Density comes in around 1.3 g/cm3, which shapes not only how it’s weighed or dispensed but also informs on blending with excipients or raw ingredients during tablet formation.
Olanzapine’s molecular weight clocks in at 312.44 g/mol. Chemists pay attention here: the balance between the thienobenzodiazepine backbone and peripheral groups influences everything from reactivity to solubility. Its melting point hovers between 195°C and 197°C, useful information for both stability testing and pharmaceutical production, where holding temperature steady matters for quality and consistency. This compound dissolves poorly in water, so formulators look to organic solvents like methanol, ethanol, or dimethyl sulfoxide to dissolve it fully. Limited aqueous solubility shapes its formulation strategy, particularly in making oral tablets or injectable preparations, and impacts bioavailability down the line. Specifications often require close control of purity (generally upwards of 98%), with detailed limits placed on common impurities, moisture content, and residual solvents. Meeting these standards isn’t just a regulatory checkbox—it directly connects to drug safety and repeatability in patient outcomes.
Before anything gets moved across borders, tracing Olanzapine’s regulatory identity matters for customs and trade. The Harmonized System (HS) Code for Olanzapine is typically 29349990, which falls under other heterocyclic compounds and specifically covers miscellaneous pharmaceutical raw materials. Proper use of the HS code helps avoid shipping delays, flags correct taxation, and ensures compliance with environmental and safety laws in both exporting and importing countries. On top of HS code, each batch carries identifiers such as lot number, Certificate of Analysis, and sometimes even a unique barcode, connecting every packet back to its manufacturing record for complete traceability.
Working with Olanzapine isn’t like handling table sugar. While finished tablets are generally safe for patients, handling the raw material calls for thorough safety protocols. Dust inhalation risks irritation to the respiratory tract or eyes, and direct skin contact with powder might trigger mild reactions. Material safety data sheets recommend using gloves, protective eyewear, lab coats, and well-functioning ventilation in spaces where raw Olanzapine is weighed or mixed. Chronic exposure at high levels in manufacturing could present additional risks, so routine monitoring plus well-maintained extraction systems help keep working environments safe. Storage has its requirements too: low humidity, cool temperatures, and tightly sealed containers extend shelf life by preventing clumping or chemical breakdown. Waste and leftovers fall under hazardous materials management, calling for compliant disposal through certified chemical waste streams to avoid environmental impact.
Olanzapine doesn’t grow on trees—it’s the result of complex organic synthesis starting with carefully selected precursors. The production journey usually involves thienobenzodiazepine scaffolds, layered through sequences of cyclization and functional group modification. Each of these steps influences the overall yield, as well as the impurity profile of the final material. Vendors frequently require documentation of the raw materials’ provenance, synthesis method, and batch-specific impurity spectrum, giving buyers insight into both quality and process reliability. This transparency is essential for pharmaceutical manufacturers pushing toward ever-stricter regulatory standards. With demand rising steadily for effective antipsychotic therapies, scaling up production means paying attention not just to chemistry but to sustainability, consistent sourcing, and environmental stewardship in solvent recovery and waste minimization.
With mental health awareness on the rise, the production and supply chain of compounds like Olanzapine hold practical significance. Interruptions or inconsistencies—whether in raw material quality, regulatory compliance or proper storage—carry downstream effects not just for pharmaceutical firms but ultimately for patients who rely on stable dosing for life-changing relief. Every aspect, from the density of the solid to the purity specifications and the handling protocols in warehouses, links directly to human health outcomes. That’s a constant reminder that chemical details are never just details—they create the foundation for effective therapies, safe products, and public trust in pharmaceutical progress. Seeking solutions to production challenges means collaborating across research labs, compliance teams, manufacturing, and logistics. It requires commitment to clear communication, openness to better technology, and never cutting corners in quality or safety, no matter the pressure to meet demand or cut costs.
